These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

453 related articles for article (PubMed ID: 33202419)

  • 41. Convalescent plasma in hospitalized pediatric and obstetric coronavirus disease 2019 (COVID-19) patients.
    Ikeda S; Benzi E; Hensch LA; Devaraj S; Hui SR; Gandhi M; Fox KA; Teruya J; Munoz FM
    Pediatr Int; 2022 Jan; 64(1):e15407. PubMed ID: 36326636
    [TBL] [Abstract][Full Text] [Related]  

  • 42. COVID-19 Convalescent Plasma for the Treatment of Immunocompromised Patients: A Systematic Review and Meta-analysis.
    Senefeld JW; Franchini M; Mengoli C; Cruciani M; Zani M; Gorman EK; Focosi D; Casadevall A; Joyner MJ
    JAMA Netw Open; 2023 Jan; 6(1):e2250647. PubMed ID: 36633846
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Potential use of convalescent plasma for SARS-CoV-2 prophylaxis and treatment in immunocompromised and vulnerable populations.
    Focosi D; Franchini M
    Expert Rev Vaccines; 2022 Jul; 21(7):877-884. PubMed ID: 34015243
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clinical predictors of donor antibody titre and correlation with recipient antibody response in a COVID-19 convalescent plasma clinical trial.
    Madariaga MLL; Guthmiller JJ; Schrantz S; Jansen MO; Christensen C; Kumar M; Prochaska M; Wool G; Durkin-Celauro A; Oh WH; Trockman L; Vigneswaran J; Keskey R; Shaw DG; Dugan H; Zheng NY; Cobb M; Utset H; Wang J; Stovicek O; Bethel C; Matushek S; Giurcanu M; Beavis KG; di Sabato D; Meltzer D; Ferguson MK; Kress JP; Shanmugarajah K; Matthews JB; Fung JF; Wilson PC; Alverdy JC; Donington JS
    J Intern Med; 2021 Apr; 289(4):559-573. PubMed ID: 33034095
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Convalescent Covid-19 plasma: Back-to-basics and ethics, and next steps.
    Garraud O; Burnouf T
    Transfus Clin Biol; 2021 Aug; 28(3):225-227. PubMed ID: 34362557
    [No Abstract]   [Full Text] [Related]  

  • 46. Passive Immunity for Coronavirus Disease 2019: A Commentary on Therapeutic Aspects Including Convalescent Plasma.
    Lindholm PF; Ramsey G; Kwaan HC
    Semin Thromb Hemost; 2020 Oct; 46(7):796-803. PubMed ID: 32526774
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Convalescent plasma for COVID-19: Donor demographic factors associated high neutralising antibody titres.
    Mehew J; Johnson R; Roberts D; Griffiths A; Harvala H
    Transfus Med; 2022 Aug; 32(4):327-337. PubMed ID: 35434868
    [TBL] [Abstract][Full Text] [Related]  

  • 48. SARS COV-2- IgG antibodies in blood donors in pandemic - A game changer for policy makers.
    Mahapatra S
    Transfus Clin Biol; 2022 Feb; 29(1):11-15. PubMed ID: 34653615
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Analysis of 52 240 source plasma donors of convalescent COVID-19 plasma: Sex, ethnicity, and age association with initial antibody levels and rate of dissipation.
    Schmidt AE; Vogel P; Chastain CA; Barnes T; Roth NJ; Simon TL
    J Clin Apher; 2022 Oct; 37(5):449-459. PubMed ID: 35815776
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Highly Potent SARS-CoV-2 Neutralization by Intravenous Immunoglobulins manufactured from Post-COVID-19 and COVID-19-Vaccinated Plasma Donations.
    Karbiener M; Farcet MR; Schwaiger J; Powers N; Lenart J; Stewart JM; Tallman H; Kreil TR
    J Infect Dis; 2021 Nov; 224(10):1707-1711. PubMed ID: 34543421
    [TBL] [Abstract][Full Text] [Related]  

  • 51. How do I… facilitate a rapid response to a public health emergency requiring plasma collection with a public-private partnership?
    Miller MJ; Skrzekut A; Kracalik I; Jones JM; Lofy KH; Konkle BA; Haley NR; Duvenhage M; Bonnett T; Holbrook M; Higgs E; Basavaraju SV; Paranjape S
    Transfusion; 2021 Oct; 61(10):2814-2824. PubMed ID: 34510475
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effects of Severe Acute Respiratory Syndrome Coronavirus 2 Strain Variation on Virus Neutralization Titers: Therapeutic Use of Convalescent Plasma.
    Nguyen D; Xiao J; Simmonds P; Lamikanra A; Odon V; Ratcliff J; Townsend A; Roberts DJ; Harvala H
    J Infect Dis; 2022 Mar; 225(6):971-976. PubMed ID: 34751775
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A trend of dropping anti-SARS-CoV-2 plaque reduction neutralization test titers over time in Canadian convalescent plasma donors.
    Drews SJ; Devine DV; McManus J; Mendoza E; Manguiat K; Wood H; Girardin R; Dupuis A; McDonough K; Drebot M
    Transfusion; 2021 May; 61(5):1440-1446. PubMed ID: 33734448
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Anti-SARS-CoV-2 virus antibody levels in convalescent plasma of six donors who have recovered from COVID-19.
    Zhang L; Pang R; Xue X; Bao J; Ye S; Dai Y; Zheng Y; Fu Q; Hu Z; Yi Y
    Aging (Albany NY); 2020 Apr; 12(8):6536-6542. PubMed ID: 32320384
    [TBL] [Abstract][Full Text] [Related]  

  • 55. COVID-19 convalescent plasma as long-term therapy in immunodeficient patients?
    Rnjak D; Ravlić S; Šola AM; Halassy B; Šemnički J; Šuperba M; Hećimović A; Kurolt IC; Kurtović T; Mačak Šafranko Ž; Polančec D; Bendelja K; Mušlin T; Jukić I; Vuk T; Zenić L; Artuković M
    Transfus Clin Biol; 2021 Aug; 28(3):264-270. PubMed ID: 33901641
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Production of hyperimmune anti-SARS-CoV-2 intravenous immunoglobulin from pooled COVID-19 convalescent plasma.
    Ali S; Uddin SM; Ali A; Anjum F; Ali R; Shalim E; Khan M; Ahmed I; M Muhaymin S; Bukhari U; Luxmi S; Khan AS; Quraishy S
    Immunotherapy; 2021 Apr; 13(5):397-407. PubMed ID: 33557591
    [No Abstract]   [Full Text] [Related]  

  • 57. Lessons learned from early compassionate use of convalescent plasma on critically ill patients with Covid-19.
    Liu M; Chen Z; Dai MY; Yang JH; Chen XB; Chen D; You H; Guo X; Leng Y; Yu L; Zhang ML; Wu X; Yang J; Gao C; Tenen DG; Chai L; Ai F
    Transfusion; 2020 Oct; 60(10):2210-2216. PubMed ID: 32770691
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The use of convalescent plasma for pediatric patients with SARS-CoV-2: A systematic literature review.
    Zaffanello M; Piacentini G; Nosetti L; Franchini M
    Transfus Apher Sci; 2021 Apr; 60(2):103043. PubMed ID: 33388249
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain.
    Yang M; Li J; Huang Z; Li H; Wang Y; Wang X; Kang S; Huang X; Wu C; Liu T; Jia Z; Liang J; Yuan X; He S; Chen X; Zhou Z; Chen Q; Liu S; Li J; Zheng H; Liu X; Li K; Yao X; Lang B; Liu L; Liao HX; Chen S
    Microbiol Spectr; 2021 Oct; 9(2):e0135221. PubMed ID: 34643438
    [TBL] [Abstract][Full Text] [Related]  

  • 60. COVID-19 Serology Data Provide Guidance for Future Deployments of Convalescent Plasma.
    Sullivan D; Casadevall A
    mBio; 2023 Jun; 14(3):e0042823. PubMed ID: 37039667
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.